TY - JOUR
T1 - Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy
AU - Keefe, Dorothy M.
AU - Elting, Linda S.
AU - Nguyen, Hoang T.
AU - Grunberg, Steven M.
AU - Aprile, Giuseppe
AU - Bonaventura, Antony
AU - Selva-Nayagam, Sudarsha
AU - Barsevick, Andrea
AU - Koczwara, Bogda
AU - Sonis, Stephen T.
N1 - Funding Information:
Acknowledgments This study was funded by unrestricted grants from Amgen and from Helsinn Healthcare made to the Triad Burden of Illness Study Research Group.
Funding Information:
Conflict of interest Drs. Aprile, Barsevick, Bonaventura, Elting, Koczwara, Nguyen and Selva-Nayagam have no additional conflicts to declare. Dr. Keefe has received research funding from Entera Healthcare, Merck and Helsinn, and has a consultancy agreement with Pfizer. She is an advisor to Soligenix. Dr. Sonis is an employee of Biomodels, is a consultant at Clinical Assistance Programs, Bio-Alliance, Izun, Piramel, Inform Genomics (founder), Pfizer, Access, Novartis, Merck and Supportive Therapeutics. He is an advisor to Avaxia, Galera, Polymedix, Synedgen, Soligenix, Pfizer and Reata. Dr. Sonis reports Advisory roles with Biomodels, LLC, Actogenix, Avaxia, BioAlliance, Galera, Izun, Polymedix, Piramal, Synedgen, Soligenix, Pfizer, Reata, Access, Novartis and Merck. He reports personal fees from Clinical Assistance Programs and Inform Genomics; in addition, Dr. Sonis has a patent US Patent 6,458,777 issued, a patent US Patent 6,663,850 issued, a patent US Patent 6,713,463 issued, a patent US Patent 6,841,578 B2 issued and a patent US Patent 7,297,123 issued.
Publisher Copyright:
© Springer-Verlag 2014.
PY - 2014/7/25
Y1 - 2014/7/25
N2 - Background: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance. Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated. To better understand the risks, symptom burden and consequences of CID, we studied patients receiving chemotherapy for colorectal cancer (CRC). Methods: One hundred and fourteen patients receiving FOLFOX (95 patients, 530 cycles), FOLFOX + monoclonal antibodies (10 patients, 49 cycles) or FOLFIRI (9 patients, 50 cycles) were enrolled. CID was identified from diaries at baseline and daily during up to 8 chemotherapy cycles using supplemental questions on the Oral Mucositis Daily Questionnaire, a valid tool for collecting patient-reported outcomes of regimen-related mucosal injury. Patients scored CID severity from 0 "none" to 10 "worst possible," and quantity from "little" to "severe" on a 5-point scale. Quality of life was measured using the FACT-G, and fatigue using the FACIT fatigue scale. Results CID occurred in 89 % of patients on FOLFIRI, 50 % on FOLFOX + monoclonal antibodies and 56 % on FOLFOX alone. The risk of a first episode was highest during Cycle 1 (35 %) and dropped to <10 % during Cycles 3-5. Patients with CID reported poorer quality of life scores than those without CID (77.1 vs 80.7). Conclusions: Diarrhea occurs more commonly than typically appreciated during chemotherapy for CRC. Risk is highest during first exposure, suggesting variable susceptibility. Identification of this high-risk subgroup for prophylaxis could improve the quality of life.
AB - Background: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance. Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated. To better understand the risks, symptom burden and consequences of CID, we studied patients receiving chemotherapy for colorectal cancer (CRC). Methods: One hundred and fourteen patients receiving FOLFOX (95 patients, 530 cycles), FOLFOX + monoclonal antibodies (10 patients, 49 cycles) or FOLFIRI (9 patients, 50 cycles) were enrolled. CID was identified from diaries at baseline and daily during up to 8 chemotherapy cycles using supplemental questions on the Oral Mucositis Daily Questionnaire, a valid tool for collecting patient-reported outcomes of regimen-related mucosal injury. Patients scored CID severity from 0 "none" to 10 "worst possible," and quantity from "little" to "severe" on a 5-point scale. Quality of life was measured using the FACT-G, and fatigue using the FACIT fatigue scale. Results CID occurred in 89 % of patients on FOLFIRI, 50 % on FOLFOX + monoclonal antibodies and 56 % on FOLFOX alone. The risk of a first episode was highest during Cycle 1 (35 %) and dropped to <10 % during Cycles 3-5. Patients with CID reported poorer quality of life scores than those without CID (77.1 vs 80.7). Conclusions: Diarrhea occurs more commonly than typically appreciated during chemotherapy for CRC. Risk is highest during first exposure, suggesting variable susceptibility. Identification of this high-risk subgroup for prophylaxis could improve the quality of life.
KW - Chemotherapy
KW - Chemotherapy-induced diarrhea
KW - Colorectal cancer
KW - Patient-reported outcomes
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=84925546303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925546303&partnerID=8YFLogxK
U2 - 10.1007/s00280-014-2526-5
DO - 10.1007/s00280-014-2526-5
M3 - Article
C2 - 25055935
AN - SCOPUS:84925546303
VL - 74
SP - 675
EP - 680
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 4
ER -